The Francis Crick Institute is delighted to announce that Stephen Mayhew has been appointed as Chief Business Officer, bringing his extensive experience in business development, partnerships, collaborations, R&D and translation to the newly created role.
Stephen joins the Crick from the Coalition for Epidemic Preparedness Innovations, CEPI, a global organisation that works to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines. As Director of Strategy and Portfolio, he was responsible for driving the development and delivery of CEPI’s strategic objectives, including planning, portfolio governance, monitoring and evaluation.
Prior to CEPI, Stephen served as a member of the executive management team of Stallergenes Greer, an allergy-focused specialty biopharmaceutical company. He also previously held senior corporate and R&D strategy positions with GlaxoSmithKline as well as scientific and business management positions across academia and industry, including roles in clinical study management, business development, and management consulting.
Stephen said, “The Crick is a world-leading research institute that embodies the strength of the UK biomedical sector in the global life sciences arena, and I am delighted to be joining as its Chief Business Officer. I look forward to working with the team, together with partners across the sector, to accelerate the translation of the Crick’s pioneering discovery research into innovative new treatments, diagnostics and technologies that benefit human health.”
Sam Barrell, deputy chief executive officer of the Crick said: “Stephen brings a wealth of experience and we are delighted that he will be joining the senior leadership team.”
Stephen holds a BSc in Biochemistry from the University of Liverpool, a PhD in Biochemistry from the University of Leeds and a MBA from Imperial College Business School.
